An Open-label, Single-arm, Multicenter, Extension Study to Evaluate the Long-term Safety and Efficacy of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Latest Information Update: 17 Sep 2024
At a glance
- Drugs Stapokibart (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
- 09 Dec 2021 Status changed from not yet recruiting to recruiting.
- 24 Nov 2021 New trial record